YMAB - Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics upgraded to Equal Weight from Underweight at Morgan Stanley

$8.60 (was $8.52)

Morgan Stanley

Aug 05, 2025 04:49 PM • TheFly

Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord

$8.60 (was $8.52)

Canaccord Genuity

Aug 05, 2025 04:49 PM • TheFly

Y-mAbs Therapeutics downgraded to Hold from Buy at Truist

$8.60 (was $8.52)

Truist Financial

Aug 05, 2025 03:26 PM • TheFly

Y-mAbs Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

$8.60 (was $8.52)

Cantor Fitzgerald

Aug 05, 2025 01:56 PM • TheFly

Y-mAbs Therapeutics downgraded to Neutral from Outperform at Wedbush

$8.60 (was $8.52)

Wedbush

Aug 05, 2025 11:07 AM • TheFly

Y-mAbs Therapeutics price target lowered to $7 from $11 at Morgan Stanley

$7.00 (was $4.85)

Morgan Stanley

Mar 05, 2025 07:51 AM • TheFly

Y-mAbs Therapeutics (YMAB) PT Lowered to $24 at BMO Capital

$24.00 (was $15.06)

Etzer Darout · BMO Capital

Nov 11, 2024 08:27 AM • StreetInsider

Truist Securities Starts Y-mAbs Therapeutics (YMAB) at Buy

$21.00 (was $12.33)

Nicole Germino · Truist Financial

Jun 28, 2024 02:02 AM • StreetInsider

Y-mAbs Therapeutics price target raised to $22 from $21 at H.C. Wainwright

$22.00 (was $12.87)

Robert Burns · H.C. Wainwright

May 10, 2024 02:41 AM • TheFly

BMO Capital on Y-mAbs Therapeutics (YMAB): 'Radiopharma Is Hot & SADA De-Risking Would Unlock Value'

$26.00 (was $14.56)

Etzer Darout · BMO Capital

Apr 05, 2024 02:30 AM • StreetInsider

Analyst Upgrades Y-mAbs On Bullish Danyelza Sales Outlook, Improved Visibility

$13.00 (was $9.89)

YMAB)to Outperform · Wedbush

May 10, 2023 11:10 AM • Benzinga